Insider · CIK 0001863633
Michael Martin Breen
Files at GTBP (GT Biopharma, Inc.). First filing -, latest -.
In brief
Michael Martin Breen files SEC Form 4 as CEO and director at GTBP (GT Biopharma, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Michael Martin Breen has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 4, 2025 | GTBP GT Biopharma, Inc. | AGrant or award Option to purchase Common Stockderivative | +100,000 | $0.00 | $0 | 100,000 | Sep 8, 2025 |
| Sep 4, 2025 | GTBP GT Biopharma, Inc. | AGrant or award Option to purchase Common Stockderivative | +100,000 | $0.00 | $0 | 100,000 | Sep 8, 2025 |
| Sep 4, 2025 | GTBP GT Biopharma, Inc. | AGrant or award Option to purchase Common Stockderivative | +100,000 | $0.00 | $0 | 100,000 | Sep 8, 2025 |
Questions about Michael Martin Breen
Answered from the filings on this page, as of the latest one.
Is Michael Martin Breen buying or selling?
Michael Martin Breen has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Michael Martin Breen's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael Martin Breen has 0.
Where does Michael Martin Breen file Form 4?
Michael Martin Breen has filed Form 4 at GTBP (GT Biopharma, Inc.) as CEO and Director. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.